Fulltext

The CDK inhibitors in cancer research and therapy

Cicenas, Jonas ; Valius, Mindaugas

In: Journal of Cancer Research and Clinical Oncology, 2011, vol. 137, no. 10, p. 1409-1418

Zum persönliche Liste hinzufügen
    Titel
    • The CDK inhibitors in cancer research and therapy
    Autor
    • Cicenas, Jonas. Department of Medicine, Institute of Anatomy, University of Fribourg, Rte. Albert- Gockel 1, 1700, Fribourg, Switzerland
    • Valius, Mindaugas. Department of Developmental Biology, Institute of Biochemistry, Vilnius, Lithuania
    Dokumententyp
    • Postprint
    Sprache
    • Englisch
    Veröffentlicht in
    • Journal of Cancer Research and Clinical Oncology, 2011, vol. 137, no. 10, p. 1409-1418. Springer-Verlag
    Andere elektronische Ausgabe
    OAI-PMH-ID
    • oai:doc.rero.ch:319512
    Summary
    Chemical compounds that interfere with an enzymatic function of kinases are useful for gaining insight into the complicated biochemical processes in mammalian cells. Cyclin-dependent kinases (CDK) play an essential role in the control of the cell cycle and/or proliferation. These kinases as well as their regulators are frequently deregulated in different human tumors. Aberrations in CDK activity have also been observed in viral infections, Alzheimer's, Parkinson's diseases, ischemia and some proliferative disorders. This led to an intensive search for small-molecule CDK inhibitors not only for research purposes, but also for therapeutic applications. Here, we discuss seventeen CDK inhibitors and their use in cancer research or therapy. This review should help researchers to decide which inhibitor is best suited for the specific purpose of their research. For this purpose, the targets, commercial availability and IC50 values are provided for each inhibitor. The review will also provide an overview of the clinical studies performed with some of these inhibitors